Props to Respert for uncovering the interview and a quick afterthought: one of our board members here recently made the comment Cyrus is operating with a script that is known to work and I agree. One of the things Cyrus comments on in the interview is noteworthy:

“ I continually tell the team that we are really fortunate. It’s a gift that we have this molecule in our hands and that we can develop it, because we have something that we really believe works. The molecule is fantastic. There is a path here to value generation”

You don’t invest time and money on a “we think or hope it might work” drug, you execute a script when the drug has been assayed and found to be of the rare earth metal type. I’m not sure who approached who that resulted in the interview but if you look at Cyrus LinkedIn profile and endorsement connections you can’t fail to notice how broad they are and bump up against quite a number of major bio pharmaceutical companies. The script known to work involves partnerships. How fortuitous for us that Cyrus is focused and disciplined, with a clear end-game in mind and connections to leverage in the process.

I was not aware there was a death in the HIV study sub population (mostly likely study extension) and coincident with the inadvertent deaths of two people from the Brazil covid19 study you might say it is reasonable for the FDA hold to be placed until such time as a composite safety and efficacy analysis is compiled. The deaths are not drug related, they are disease or comorbidity related. The FDA documents take time; what Amarex was contracted to do and failed Cyrus and Cytodyn are now stepping up to do…the hold lift Cyrus pointed out is both a priority and a gating step to other components of the script. My sense is that it is imminent.